article thumbnail

UK MHRA publishes guidance on medicines containing valproate

Pharmaceutical Technology

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published updated guidance on valproate-containing medicines.

article thumbnail

Resolving challenges with product recovery in biopharma manufacturing

Pharmaceutical Technology

Breakthroughs in therapies containing monoclonal antibodies (mAbs) are showing ever-greater potential in treating a range of diseases, alongside biopharma manufacturers facing the challenge of keeping up with demand for production while controlling costs. Increasing product yield is the most fundamental way to achieve this.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How API CMOs can improve containment capabilities without facility acquisition

Pharmaceutical Technology

According to GlobalData analysis, specialist small molecule API capabilities such as containment or controlled substances are driving large contract manufacturing organisations (CMOs) to acquire facilities. Flexible containment solutions for potent APIs. Partnering with containment experts.

article thumbnail

Tetra and Cellvera partner to develop oral Covid-19 treatment

Pharmaceutical Technology

A first-in-human drug product, ARDS-003 contains the active pharmaceutical agent, Onternabez. We look forward to working jointly with Cellvera to bring this combination drug product forward to improve treatment options for patients worldwide.”. Onternabez is a selective full agonist of the type 2 cannabinoid receptor (CB2R).

article thumbnail

Optimising biopharma production through process intensification

Pharmaceutical Technology

Process intensification can loosely be described as making more product with the same or fewer resources. The appeal of process intensification continues to grow in the biopharma industry as a means of not only increasing the productivity, but also improving sustainability. Existing technologies could also be run in a different way.

article thumbnail

Early decisions to de-risk the transition to combination products

Bio Pharma Dive

Speeding up the drug development process through a less optimized containment and delivery system may have been an option in the past, but both expectations and the competitive environment are changing.

article thumbnail

Clover collaborates with Kyuan Trade to launch AdimFlu-S (QIS) in China

Pharmaceutical Technology

Clover Biopharmaceuticals has established a commercial collaboration with Keyuan Xinhai (Beijing) Medical Products Trading (Kyuan Trade) for the launch of its quadrivalent seasonal influenza vaccine, AdimFlu-S (QIS), in China. The vaccine contains haemagglutinin from four influenza virus strains, two A and two B.

Vaccine 262